CHG-2024-0293

Formulation Change for Upadacitimab. Facility Change for Upadacitimab — routine update. Impacts 7 markets and 1 variations.

Change Number
CHG-2024-0293
Type
Formulation Change
Product
Upadacitimab
Status
Draft
Owner
Dmitri Volkov
Initiated
2023-07-21
Description

Facility Change for Upadacitimab — routine update

Impacted Markets (7)
EU — European UnionBR — BrazilCA — CanadaFR — FranceIT — ItalyAR — ArgentinaZA — South Africa
Impacted Modules
3.2.P.34.2.13.2.P2.3.P
Linked Variations (0)
Variation #TypeApplicationStatusSubmittedApproved